Submitted by Jack Attack on Mon, 12/28/2015 - 1:29pm Currently, how confident are you in your ability to: * Please use the scale: 1=Not at all confident , 2=Not very confident, 3=Somewhat confident, 4=Confident, 5=Extremely confident 12345 Develop personalized treatment plans for patients with dyslipidemia? Develop personalized treatment plans for patients with dyslipidemia? - 1 Develop personalized treatment plans for patients with dyslipidemia? - 2 Develop personalized treatment plans for patients with dyslipidemia? - 3 Develop personalized treatment plans for patients with dyslipidemia? - 4 Develop personalized treatment plans for patients with dyslipidemia? - 5 Understand current science and utilize guidelines when treating patients with dyslipidemia? Understand current science and utilize guidelines when treating patients with dyslipidemia? - 1 Understand current science and utilize guidelines when treating patients with dyslipidemia? - 2 Understand current science and utilize guidelines when treating patients with dyslipidemia? - 3 Understand current science and utilize guidelines when treating patients with dyslipidemia? - 4 Understand current science and utilize guidelines when treating patients with dyslipidemia? - 5 Four lines of evidence to suggest LDL is a key driver for heart attacks are mentioned in the video: observational epidemiology, human genetics, experimental studies and randomized controlled trials in humans. The Framingham Heart Study, an ongoing initiative beginning in 1948 that has led to identification of major cardiovascular disease (CVD) risk factors, best fits under which line of evidence? * Observational epidemiology Human genetics Experimental studies Randomized controlled trials in humans When assessing for Familial Hypercholesterolemia (FH), which of the following factors are a consideration? * Corneal arcus Cholesterol levels Family history of xanthoma, high cholesterol, & premature atherosclerosis All of the above are considerations when assessing for FH In the HIJ-Proper Trial, an analysis of 1,734 acute coronary syndrome (ACS) patients from 19 hospitals in Japan, participants were randomized to either pitavastatin monotherapy or pitavastatin plus ezetimibe, with a minimum follow-up of three years. Which of the following best describes the key finding with regards to primary endpoint event rates? * The number of primary endpoint events in the pitavastatin plus ezetimibe treatment arm was significantly higher that that of the pitavastatin monotherapy arm. The number of primary endpoint events in the pitavastatin plus ezetimibe treatment arm was significantly lower that that of the pitavastatin monotherapy arm. Overall, there was no statistically significant difference in primary endpoint event rates in the pitavastatin plus ezetimibe arm compared to pitavastatin monotherapy arm. Due to the substantial lack of follow-up in the pitavastatin plus ezetimibe treatment arm, primary endpoint event rates could not be determined. The objective of ODYSESSY ESCAPE study was to evaluate the effect of alirocumab 150 mg Q2W on the frequency of lipoprotein apheresis in patients with heterozygous FH. Approximately what percentage of the patient population no longer required apheresis during the trial period? * 20% 40% 60% 80% True or False: In the 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias, the goal of a high-risk primary prevention patient being treated with a PCSK9 inhibitor is an LDL level less than 100 mg/dL. * True False Data presented at the ESC congress focused on individuals who do not meet LDL cholesterol goals, asking the question ‘How many patients with atherosclerotic cardiovascular disease would need a PCSK9 inhibitor?’ After intensification with statins, assuming no tolerability issues, approximately 70% of atherosclerotic cardiovascular disease (ASCVD) patients can achieve LDL-C goal of (1.8 mmol/L). What was the primary reason for this? * Many ASCVD patients not at LDL-C goal were not adhering to treatment Many ASCVD patients not at LDL-C goal were not on maximal oral lipid-lowering therapies (LLT) Many ASCVD patients not at LDL-C goal were not being monitored correctly, and receiving little follow-up Many ASCVD patients not at LDL-C goal were not dieting and exercising as recommended In the Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE) Trial, an open-label, 3-year study, 2442 patients with a history of coronary heart disease (CHD) were randomized to either usual care or forced titration. How was CHD history defined in this study? * CHD was defined as having acute myocardial infarction (MI) (> 3 months before screening) CHD was defined as having percutaneous transluminal coronary angioplasty (PTCA) (> 6 months before screening) CHD was defined as having a coronary artery bypass graft (CABG) or unstable angina (> 3 months before screening) All of the above were methods of defining CHD history in the ALLIANCE Trial. Please take a moment to reflect on your current use of the practice strategies discussed in this activity. You will not be graded on your responses. Indicate how often you CURRENTLY use each of the following clinical practice strategies for your patients with dyslipidemia. * Your Current Use: 1=Never, 2=Not often, 3=Sometimes, 4=Often, 5=Always, 6=N/A 123456 Utilize existing guidelines and recommendations when treating patients with dyslipidemia. Utilize existing guidelines and recommendations when treating patients with dyslipidemia. - 1 Utilize existing guidelines and recommendations when treating patients with dyslipidemia. - 2 Utilize existing guidelines and recommendations when treating patients with dyslipidemia. - 3 Utilize existing guidelines and recommendations when treating patients with dyslipidemia. - 4 Utilize existing guidelines and recommendations when treating patients with dyslipidemia. - 5 Utilize existing guidelines and recommendations when treating patients with dyslipidemia. - 6 Incorporate PCSK9 inhibitors to improve outcomes in dyslipidemia patients. Incorporate PCSK9 inhibitors to improve outcomes in dyslipidemia patients. - 1 Incorporate PCSK9 inhibitors to improve outcomes in dyslipidemia patients. - 2 Incorporate PCSK9 inhibitors to improve outcomes in dyslipidemia patients. - 3 Incorporate PCSK9 inhibitors to improve outcomes in dyslipidemia patients. - 4 Incorporate PCSK9 inhibitors to improve outcomes in dyslipidemia patients. - 5 Incorporate PCSK9 inhibitors to improve outcomes in dyslipidemia patients. - 6 Apply knowledge from clinical trial data in developing individualized treatment plans to maximize the number of patients meeting LDL-C goals. Apply knowledge from clinical trial data in developing individualized treatment plans to maximize the number of patients meeting LDL-C goals. - 1 Apply knowledge from clinical trial data in developing individualized treatment plans to maximize the number of patients meeting LDL-C goals. - 2 Apply knowledge from clinical trial data in developing individualized treatment plans to maximize the number of patients meeting LDL-C goals. - 3 Apply knowledge from clinical trial data in developing individualized treatment plans to maximize the number of patients meeting LDL-C goals. - 4 Apply knowledge from clinical trial data in developing individualized treatment plans to maximize the number of patients meeting LDL-C goals. - 5 Apply knowledge from clinical trial data in developing individualized treatment plans to maximize the number of patients meeting LDL-C goals. - 6 Leave this field blank
